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Purpose: Image guided radiation therapy (IGRT) has become common practice for both
photon and proton radiation therapy, but there is little consensus regarding its application in
the pediatric population. We evaluated clinical patterns of pediatric IGRT practice through an
international pediatrics consortium comprised of institutions using either photon or proton
radiation therapy.
Methods and materials: Seven international institutions with dedicated pediatric expertise
completed a 53-item survey evaluating patterns of IGRT use in definitive radiation therapy for
patients ≤21 years old. Two institutions use proton therapy for children and all others use IG photon
therapy. Descriptive statistics including frequencies of IGRT use andmeans and standard deviations for
planning target volume (PTV) margins by institution and treatment site were calculated.Sources of support: This research was partially supported through an Elekta research grant with all institutions being members of the Elekta Pediatric
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Practice patterns of pediatric IGRT 337Practical Radiation Oncology: September-October 2014Results: Approximately 750 pediatric patients were treated annually across the 7 institutions. IGRT
was used in tumors of the central nervous system (98%), abdomen or pelvis (73%), head and neck
(100%), lung (83%), and liver (69%). Photon institutions used kV cone beam computed tomography
and kV- and MV-based planar imaging for IGRT, and all proton institutions used kV-based planar
imaging; 57% of photon institutions used a specialized pediatric protocol for IGRT that delivers lower
dose than standard adult protocols. Immobilization techniques varied by treatment site and institution.
IGRTwas utilized daily in 45% andweekly in 35% of cases. The PTVmargin with use of IGRT ranged
from 2 cm to 1 cm across treatment sites and institution.
Conclusions:Use of IGRT in children was prevalent at all consortium institutions. There was treatment
site-specific variability in IGRT use and technique across institutions, although practices varied less at
proton facilities. Despite use of IGRT, there was no consensus of optimum PTV margin by treatment
site. Given the desire to restrict any additional radiation exposure in children to instances where the
exposure is associated with measureable benefit, prospective studies are warranted to optimize IGRT
protocols by modality and treatment site.
© 2014 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).Introduction
Image guided radiation treatment (IGRT) has become
common practice for multiple tumor types in the adult
population and is frequently used in management of the
pediatric population as well. Although there is no
consensus definition, IGRT generally refers to frequent,
serial imaging performed in the treatment room prior to
delivery of radiation therapy, affording improved locali-
zation of the target and normal structures.1-3 Such
pretreatment IGRT allows for more precise and accurate
radiation delivery, permitting for reduction in treatment
margins and subsequent dose escalation strategies,4,5
which have been associated with improved local
control.6,7 Moreover, serial IGRT can identify changes
in target and normal tissue volumes over the course of
radiation therapy, allowing for the possibility of adaptive
radiation regimens.8,9
Methods for image guidance include planar and
volumetric imaging as well as localization and tracking
of internal or surface markers.1,10 Commonly employed
planar strategies include megavoltage (MV) images
derived from the treatment x-ray beam (known as portal
imaging) and kilovoltage (kV) images from x-ray
devices in the treatment room. Planar radiographs can
also be continuously acquired to allow for real-time
fluoroscopic monitoring. Yet MV- and kV-based planar
imaging often lack adequate contrast for soft tissue
delineation; as such, these images are generally directed
at surrogate bony landmarks or fiducials as opposed to
the actual treatment target. Consequently, deformation
in target volumes or movement of the target may go
undetected. Conversely, volumetric imaging strategies
such as cone beam computed tomography (CBCT) can
offer a means for 3-dimensional target localization with
adequate soft tissue and bone resolutions for many
treatment sites.11 Yet, repeated pretreatment CT scansare associated with increased treatment time, monetary
cost, and radiation dose of up to approximately 3 cGy
per CBCT scan.11,12
These limitations may be especially important to
consider when choosing optimal IGRT regimens in the
pediatric population, for whom there is particular concern
for potential late effects related to both cumulative
radiation dose and distribution of radiation dose.13-15
Moreover, the increased time required to complete IGRT
protocols may reduce the older pediatric patient’s
tolerance for maintaining the treatment position or
lengthen the younger patient’s time under anesthesia.
There is a paucity of studies in the literature examining
the use of IGRT in the pediatric population, with no
consensus guidelines for its appropriate application. Thus,
to better understand the range of IGRT practices currently
employed, this study evaluates clinical patterns of
pediatric IGRT use through an international pediatrics
consortium comprised of institutions using either photon
or proton radiation therapy.Methods and materials
Consortium participants
Pediatric radiation oncologists at 9 international insti-
tutions recognized for having dedicated pediatric expertise
were selected to participate in a research consortium
evaluating patterns of IGRT practice in the treatment of
patients ≤21 years old. For definitive pediatric IGRT
cases, 5 sites deliver photon IMRT alone, 1 site uses proton
therapy alone, and 1 site utilizes both proton and photon
therapy. Image guidance strategies employed at photon
institutions within the consortium include in-room kV- and
MV- planar imaging and kV-CBCT; all proton therapy was
performed with kV-planar IGRT.
Table 1 Estimated number of pediatric cases treated with radiation therapy per year and percent of cases by treatment location
across consortium institutions
Consortium
institution
Estimated pediatrics
cases per year
Percent of pediatrics cases treated by treatment sites
Photons Protons CNS A&P H&N Lung Liver Other
1 22 13 45% 20% 10% 10% 1% 15%
2 — 100-120 65% 15% 20% — — —
3 141 — 45% 6% 11% 13% — 26%
4 150 — 26% 12% 8% b1% — 54%
5 150 — 25% 25% 5% — — 45%
6 100 — 34% 15% 6% 6% 3% 36%
7 60 — 50% 20% 15% 5% 1% 9%
Total 623 113-133 41% 16% 11% 5% 1% 26%
A&P, abdomen/pelvis; CNS, central nervous system; H&N, head and neck.
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Each consortium institution was provided with a 53-
item survey comprised of mixed dichotomous, rank order,
constant sum, and open-ended questions. Seven of the 9
consortium institutions completed the survey. Responses
were collected and coded by 2 physicians affiliated with
the consortium. Descriptive statistics including frequen-
cies, means, and standard deviations were calculated using
Excel software (Microsoft Corporation, Redmond, WA).
Measures
Treatment population characteristics
Consortium institutions self-reported the annual esti-
mated number of pediatrics patients treated at their
facilities. These estimates were stratified by the following
radiation treatment sites: central nervous system (CNS);
abdomen or pelvis (A&P); head and neck (H&N); lung;
liver; and other sites.
IGRT characteristics
Type and frequency of IGRT as well as the percent of
patients treated with IGRT by treatment site were recorded
and stratified by proton versus photon therapy. Prevalence
of IGRT use was separately collected for common
pediatric cancer types. Target localization technique and
immobilization strategy used for each treatment site was
elicited via open-ended questions. Also queried was the
use of and attitudes toward a low- versus standard-
radiation dose IGRT protocol for pediatric patients.
Planning target value expansions
In accordance with ICRU Report 83,16 consortium sites
used modern concepts of volume determination for planning
in a majority of cases, with a planning target volume (PTV)
expansion applied to a clinical target volume (CTV) to
account for setup uncertainties and target motion. Differencesin PTV expansions applied with and without employment of
IGRT by treatment site were recorded. For institutions that
provided a range of PTVs used for a specified treatment site,
the means and standard deviations of the maximum value
were reported.
Results
Prevalence of IGRT use
Consortium treatment demographics
In total, an estimated 623 patients were treated with
photon therapy and up to 133 patients were treated with
proton therapy annually across facilities. The cental
nervous system (CNS) was the most frequent treatment
site for 4 out of 7 institutions, comprising from 25% to
65% of treated cases across facilities. Among proton
institutions, CNS and head and neck (H&N) were the most
common sites of treatment. Table 1 details the estimated
annual number of pediatric cases and their treatment sites
across consortium institutions.
Prevalence of IGRT use
Figure 1 shows the percent of pediatric cases treated with
IGRT across consortium institutions. Both proton facilities
used kV-planar IGRT for 100% of proton cases. One photon
institution utilized IGRT in 100% of cases, with variability
in the prevalence of IGRT use across the remaining photon
facilities depending on treatment site. IGRT was consis-
tently employed in nearly all CNS cases (90%-100%) and in
100% of H&N cases across institutions. The most
inconsistent site for application of IGRT was the abdomen
or pelvis (A&P) site, with IGRT use ranging from 20% to
100% of cases across consortium facilities.
IGRT use in common pediatric tumors
The prevalence of IGRT use in management of
common pedriatic tumors varied by tumor type. All
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Figure 1 Percent of pediatrics cases treated with image guided
radiation therapy (IGRT) across consortium institutions. (CNS,
central nervous system; A&P, abdomen/pelvis; H&N, head and
neck; *, includes photon and proton therapy; †, proton therapy only.)
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A&P sarcoma, and rhabdomyosarcoma. A majority of
facilities relied on IGRT for management of medulloblas-
toma (5/6 reporting institutions), neuroblastoma (5/7), and
extremity sarcoma (5/6), whereas a minority used IGRT
for Wilm’s tumor cases (2/5). In the treatment of
rhabdomyosarcoma, 3/6 facilities used IGRT in all cases,
with 5/6 using IGRT for either abdominal or pelvic sites,
and 6/6 using IGRT for H&N sites.
IGRT technique
IGRT imaging modality
Imaging modalities for IGRT included kV-CBCT in 6/6
photon institutions, kV-planar images in 4/7 institutions
including both proton facilitities, and MV (portal)-planar
images in 1 institution. One institution also utilized a body
surface scanning technique for IGRT.
Immobilization
For CNS sites, all photon institutions used mask-based
immobilization, with 1 facility adding a vacuum bag to the
mask setup. Proton institutions reported use of thermo-
plastic mask, head frame, and combination bite block and
plastic cap immobilization. The A&P sites were immobi-
lized with vacuum bags in 5 of 7 institutions, with 1
facility adding a plastic mask to the vacuum bag setup.
One photon institution noted use of an alpha cradle with or
without a wingboard for treatment of A&P tumors. For
H&N sites, all institutions reported using mask-based
immobilization, with 1 facility adding a vacuum bag to the
mask setup and another facility using shoulder retractors.
Three institutions specified use of a long mask for H&N
treatment. For lung and liver cases, immobilization
devices included vacuum bag with and without use of a
plastic mask, wingboard alone, and combination wing-
board and alpha cradle approaches.Target localization
For photon-based IGRT in CNS site, all institutions
aligned pretreatment imaging to bony landmarks. For IGRT
in H&N sites, all facilities used alignment to bone, with 2
also using soft tissue alignment. For IGRT in A&P sites, all
institutions noted alignment to soft tissue, with 3 facilities
also relying on alignment to bone and 1 utilizing clips.
Conversely, for IGRT in lung sites, both soft tissue
alignment (5 out of 6 reporting facilities) and bony
alignment (4 out of 6 reporting facilities) were common.
Between the 2 institutions treating with proton
therapy, 1 facility described localization with daily
orthogonal kV imaging and daily field imaging. The
other institution reported use of kV imaging with
alignment to fiducial markers.
Frequency of IGRT
At least half of the consortium institutions employed
IGRT on a daily basis for CNSbA&P and H&N sites. One
institution employed a regimen of daily as well as 2-3
times weekly IGRT, presumably utilizing different
imaging modalities. Figure 2 shows the percent of
institutions using daily, weekly, or other regimens of
IGRT by treatment sites.
Use of IGRT dose protocol
Four institutions reported using a different IGRT dose
protocol for treatment of pediatric versus adult popula-
tions. Of the facilities employing a pediatric dose protocol,
only 1 varied the dose protocol for different age strata
within the pediatric population. Five institutions noted that
image quality was the most important consideration
regarding the use IGRT for pediatric patients, whereas 1
facility reported that dose minimization was the most
important concern and 1 facility felt that these consider-
ations were of equal importance.
PTV expansions
Of the 6 institutions using photons, half reported use of
different PTV expansions when treating with versus without
IGRT. Regarding the rationale used by providers for
selecting PTV expansion values with IGRT for a given
site, 1 institution stated that the decision was based on data
from the literature, 1 cited use of both literature and clinical
data, and 1 used margins suggested by Children's Oncology
Group (COG) protocols. Rationale for expansions used for
non-IGRT management was not specifically queried.
Table 2 shows the means and standard deviations of
PTV expansions used by treatment site, demonstrating that
PTV expansions were smaller for CNS, A&P, H&N, and
lung sites when IGRT is employed.
While the PTV expansions used for CNS differed only
minimally across photon facilities (ranging from 0.3 cm to
0.5 cm regardless of IGRT use), there was notable
institutional variability in the ranges of PTV expansions
used in A&P (ranging 0.5 cm to 1 cm regardless of IGRT
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Figure 2 Percent of consortium institutions using varying
image guided radiation therapy (IGRT) frequency by treatment
site. (A&P, abdomen/pelvis; CNS, central nervous system;
H&N, head and neck; *, includes 3 times weekly, 2 times
weekly, and combination imaging frequency regimens.)
340 S.R. Alcorn et al Practical Radiation Oncology: September-October 2014use), H&N (ranging from 0.3 cm to 0.5 cm with IGRT and
0.5 to 0.7 cm without IGRT), lung (ranging from 0.5 cm to
2 cm with IGRT and 0.7 cm to 2 cm without IGRT), and
liver sites (ranging from 0.5 cm to 1 cm with IGRT and
0.7 cm to 1 cm without IGRT). The PTV expansions
applied to “other” sites did not vary with IGRT use.
For management with protons, 1 institution reported
PTV expansions of 0.2 cm for CNS and 0.2 to 0.3 cm for
H&N sites. The other institution specified use of an
aperture size of 0.5 cm for vertebral body, 0.3 cm for
cranial, 0.5 cm for A&P, and 0.3 cm for H&N sites, with a
3.5% range uncertainty for the distal margin. Lung and
liver expansions were noted to be motion dependent.Discussion
In this review of IGRT practices across several
international institutions with dedicated pediatric expertise
we find that use of IGRT is prevalent among all
institutions, but with variability in its application acrossTable 2 Mean and standard deviation of maximum PTV expansion
by treatment site for photon therapy
Treatment
site
PTV expansion used without IGRT
No. Mean Standard deviati
CNS 6 0.48 0.04
A&P 5 0.84 0.23
H&N 6 0.53 0.08
Lung 5 1.24 0.51
Liver 2 0.85 0.21
Other 2 0.85 0.21
A&P, abdomen/pelvis; CNS, central nervous system; H&N, head and neck;facilities by treatment site. To our knowledge, this is the
first international multi-institutional study to evaluate
clinical patterns of pediatric IGRT for a range of treatment
sites. Moreover, it is the first of its kind to compare
pediatric IGRT use between photon and proton therapy.
Across institutions, IGRT was used over a wide variety
of tumor locations including CNS, A&P, H&N, lung, and
liver sites. The greatest concordance in IGRT practices
among consortium institutions were for CNS and H&N
sites; almost 100% of cases were treated with IGRT, with
near-perfect consensus on the requirement for daily IGRT,
the practice of alignment based on bony anatomy, and the
use of mask-based immobilization. Institutional agreement
on frequent IGRT use in these sites is likely driven by the
need to increase precision in an effort to limit dose to
nearby structures such as the brainstem, optic structures,
and spinal cord for which acute and late toxicities could be
particularly morbid. The consensus on bony alignment for
IGRT is presumably influenced by poor visualization of
CNS and H&N soft tissue targets on noncontrast planar or
volumetric imaging as well as lack of fiducial marker use
at these locations, leaving little option other than reliance
on bone for IGRT alignment. Moreover, there was
minimal variability in the PTV expansions used for CNS
and H&N sites managed with IGRT. This may reflect a
general confidence in the immobilization capacity and
repositioning accuracy associated with thermoplastic
masks for CNS and H&N tumors.17,18
Conversely, there was considerably more variability in
IGRT practices for A&P, lung, and liver sites across
institutions. In part, the inconsistency may reflect
heterogeneity of tumor presentation and the smaller
numbers of cases within these sites. For example, the
relative position of an A&P tumor to a bony landmark may
differentially affect the utility of IGRT and the decision for
selecting a bony versus a soft-tissue site for IGRT
localization. Moreover, strategies for management of
internal target movement due to respiratory motion such
as active breathing control, respiratory gating, and use of
4-dimensional CT for radiation planning can differ by
institution. The chosen strategy would be expected tos used with and without image guided radiation therapy (IGRT)
PTV expansion used with IGRT
on No. Mean Standard deviation
6 0.38 0.10
5 0.72 0.26
6 0.45 0.08
5 1.08 0.54
2 0.85 0.21
2 0.85 0.21
PTV, planning target volume.
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immobilization, IGRT modality and frequency, and PTV
expansions used.
Although limited by the small number of proton
versus photon facilities evaluated, there was a greater
degree of agreement in IGRT practices between
institutions using proton therapy. Of note, both proton
facilities used daily IGRT in 100% of cases. Given the
sharp dose falloff characterizing proton radiation, it is
particularly necessary to account for setup uncertainties
and internal motion, as small changes in target position
relative to the beam path can significantly affect target
coverage at the distal edge of the dose distribution.19,20
Moreover, the proton facilities treated a high proportion
of CNS and H&N sites; as described, treatment factors
unique to management of these tumors may make
these sites more amenable to consistent IGRT practice
across institutions.
Regarding PTV expansions, half of the institutions
using photon therapy did not vary their expansions on the
basis of IGRT. This, combined with a relatively wide
range of PTV margins used across institutions, reflects
limited consensus on appropriate expansions for the
pediatric population. Yet such consensus is particularly
important in the management of children, where there is
high priority on reducing radiation dose when feasible in
an effort to limit the risk of long-term treatment-related
toxicity. Thus, estimates of acceptable PTV expansions
derived through the collection of multi-institutional
residual offset data would be useful in providing insight
for clinical decision making in this population. However, it
should be noted that such general recommendations would
need to be interpreted by individual institutions within the
context of the clinical scenario as well as facilities-specific
features of treatment machines and imaging modalities
employed, all of which may affect the degree of systematic
and random error for which the PTV margin must account.
While a majority of facilities used a lower dose protocol
for pediatric patients, most stated that image quality was of
greater importance than dose minimization in pediatric
IGRT. Ideally, low-dose image guidance protocols that
still maintain image quality should be used if possible
when appropriate for the pediatrics population.
In conclusion, our results suggest that IGRT is
commonly used for radiation delivery in the management
of pediatric tumors but that there is notable variability in
when and how it is employed among institutions for a
given treatment site. These data highlight the need for
consensus recommendations to guide clinical decision
making for IGRT in the treatment of children. To address
some of these gaps, our pediatrics consortium is working
to develop a protocol for the use of low-dose CBCT in the
management of pediatric CNS tumors and to collectmulti-institutional data for CBCT setup accuracy in
children to inform consensus and site-specific PTV
expansion recommendations.References
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